• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEPH

    Nephros Inc.

    Subscribe to $NEPH
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

    IPO Year:

    Exchange: NASDAQ

    Website: nephros.com

    Recent Analyst Ratings for Nephros Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Nephros Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Nephros Inc.

      8-K - NEPHROS INC (0001196298) (Filer)

      6/16/25 4:15:39 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Nephros Inc.

      10-Q - NEPHROS INC (0001196298) (Filer)

      5/15/25 4:00:45 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      5/8/25 4:15:47 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Nephros Inc.

      DEFA14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:16:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Nephros Inc.

      DEF 14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:15:38 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Nephros Inc.

      8-K - NEPHROS INC (0001196298) (Filer)

      4/28/25 4:15:15 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NEPHROS INC (0001196298) (Filer)

      3/31/25 9:24:18 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Nephros Inc.

      10-K - NEPHROS INC (0001196298) (Filer)

      3/24/25 11:13:49 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      3/6/25 4:15:34 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Inc. filed SEC Form 8-K: Leadership Update

      8-K - NEPHROS INC (0001196298) (Filer)

      3/4/25 4:05:16 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    Nephros Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley FBR initiated coverage on Nephros with a new price target

      B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

      1/26/21 6:12:57 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care